Olanzapine versus placebo and haloperidol: Acute phase results of the North American Double-Blind Olanzapine Trial

Neuropsychopharmacology

Volumn 14, Issue 2, 1996, Pages 111-123

  Beasley Jr , Charles M ^a   Tollefson, Gary ^a   Tran, Pierre ^a   Satterlee, Winston ^a   Sanger, Todd ^a   Hamilton, Susan ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Acute; Antipsychotic; Atypical; Double blind; Haloperidol; Olanzapine; Placebo; Schizophrenia

Indexed keywords

HALOPERIDOL; OLANZAPINE; PLACEBO; PROLACTIN;

ADULT; AGITATION; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVOUSNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE;

EID: 0030065502     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0893-133X(95)00069-P     Document Type: Article

References (32)

1. American Psychiatric Association Task Force on Nomenclature and Statistics (1987): Diagnostic and Statistical Manual of Mental Disorders, 3rd ed, revised. Washington, DC, APA Press
2. Andreasen NC (1982): Negative symptoms in schizophrenia. Arch Gen Psychiatry 39:784-788
3. Barnes TR (1989): A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676
4. Bauer D, Gaertner MJ (1983): Wirkungen der Neuroleptika auf die Leberfunktion das blutbildende System, den Blutdruck und die Temperaturregulation. Pharmacopsychiatry 16:23-29
5. Beasley CM, Sayler ME, Potvin JH (1993): Fluoxetine versus amitriptyline in the treatment of major depression: A multicenter trial. Int Clin Psychopharmacol 8:143-149
6. Casey DE (1989): Clozapine: Neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99:S47-S53
7. Casey DE (1992): What makes a neuroleptic atypical? In Meltzer HY (ed), Novel Antipsychotic Drugs. New York, Raven, pp 241-251
8. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W (1993): A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients. J Clin Psychopharmacol 13:25-40
9. Fuller RW, Snoddy HD (1992): Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate. Res Commun Chem Pathol Pharmacol 77:87-93
10. Gaertner HJ, Fisher E, Hoss J (1989): Side effects of clozapine. Psychopharmacology 99:S97-S100
11. Guy W (1976): ECDEU Assessment Manual for Psychopharmacology, revised version. Bethesda, MD, US Department of Health, Education and Welfare
12. Hemrick-Luecke SK, Bymaster FP, Falcone JF, Moore NA, Tye NC, Fuller RW (21 May 1993 and 7-12 November 1993): Effect of olanzapine on rat brain receptor binding, acetylcholine levels and monoamine turnover. Tenth Annual Society for Neuroscience Meeting, Indianapolis Chapter. Indianapolis, IN. Twenty-third Annual Society for Neuroscience Meeting. Washington, DC
13. Kane JM, Cooper TB, Sachar EJ, Halpern FS, Bailine S (1981): Clozapine: plasma levels and prolactin response. Psychopharmacology 73:184-187
14. Leppig M, Bosch B, Naber D, Hippius H (1989): Clozapine in the treatment of 121 out-patients. Psychopharmacology 99:577-579
15. Marder SR, Meibach RC (1994): Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835
16. Meltzer HY (1992): The mechanism of action of clozapine in relation to its clinical advantages. In Meltzer HY (ed), Novel Antipsychotic Drugs. New York, Raven, pp 1-13
17. Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS (1979): Effect of clozapine on human serum prolactin levels. Am J Psychiatry 136:1550-1555
18. Montgomery S, Beasley CM, Tye NC (July 19-22, 1992): Olanzapine: An open label study in schizophrenia. Vancouver, BC, Second International Conference on Schizophrenia
19. Moore NA, Calligaro DO, Wong TD, Bymaster F, Tye NC (1993): The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 2:281-293
20. Moore NA, Rees G, Sanger G, Tye NC (1994): Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 5:196-202
21. Moore NA, Tye NC, Axton MS, Risius FC (1992): The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262:2:545-551
22. Naber D, Leppig M, Grohmann R, Hippius H (1989): Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia-a retrospective study of 387 patients. Psychopharmacology 99: S73-S76
23. Rasmussen K, Stockton ME (December 12-17, 1993): Olanzapine, a novel atypical antipsychotic, has electrophysiologic effects on A9 and A10 dopamine neurons similar to clozapine. Honolulu, HI, American College of Neuropsychopharmacology
24. SAS Institute Inc (1990): SAS/STAT User's Guide, vol 1 & 2, 4th ed, 6th version. Cary, NY, SAS Institute
25. Seeman P, Van Tol HHM (1993): Dopamine receptor pharmacology. Curr Opin Neurol Neurosurg 6:602-608
26. Simpson GM, Angus JW (1970): A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212: 11-19
27. Stark P, Hardison CD (1985): A review of multicenter controlled studies of fluoxetine versus imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 46:53-58
28. Stockton ME, Rasmussen K (November 7-12, 1993): A comparison of olanzapine and clozapine effects on dopamine neuronal activity: An electrophysiologic study. Washington, DC, Twenty-third Annual Meeting of the Society for Neuroscience
29. Tye NC, Moore NA, Rees G, Sanger G, Calligaro DO, Beasley CM (July 18-22, 1992): Preclinical pharmacology of olanzapine: A novel "atypical" antipsychotic agent. Vancouver, BC, Second International Conference on Schizophrenia
30. Van Putten T, Marder SR, Mintz J (1990): A controlled dose comparison of haloperidol in newly admitted schizophrenia patients. Arch Gen Psychiatry 47:754-758
31. Woerner MG, Mannuzza S, Kane JM (1988): Anchoring the BPRS: An aid to improved reliability. Psychopharmacol Bull 24:112-117
32. Wong DT, Moore NA, Calligaro O, Bymaster FP, Seeman P (June 6-12, 1993): The preclinical pharmacology of olanzapine, a novel antipsychotic. Rio de Janeiro, Brazil, Ninth World Congress of Psychiatry